Document is current
Any future updates will be listed below
-
Authors
Asciolla, James J.
Wu, Xuewei
Adamopoulos, Christos https://orcid.org/0000-0001-6323-4216
Gavathiotis, Evripidis https://orcid.org/0000-0001-6319-8331
Poulikakos, Poulikos I. https://orcid.org/0000-0001-6071-9963
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA285713, R01 CA240362, R01CA238229, R01CA223243, R01CA178394, P30CA013330, P30AG038072)
V Foundation for Cancer Research
Melanoma Research Alliance
Melanoma Research Foundation
Irma T. Hirschl Trust
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (P01AG031782)
- License Information
-
More Information
Article History
Received: 27 July 2022
Accepted: 9 December 2024
First Online: 30 January 2025
Competing interests
: X.W. and P.I.P. hold a patent on CDK4/6-directed degradation (WO/2018/106870). P.I.P reports research funding to his institution by Verastem Oncology and Enliven Therapeutics for projects unrelated to this work and consulting fees from Nuvalent, Blueprint Medicines, Belharra Therapeutics and Fore-Bio. E.G. reports compensation for consulting or equity ownership from BaxGen Therapeutics, BeanPod Biosciences, Comorin Therapeutics, Life Biosciences and Stelexis Biosciences for projects unrelated to this work. All other authors declare no competing interests.
